Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
International Journal of Clinical Pharmacy · 2025
DOI: 10.1007/s11096-025-02041-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy, 2025. Verfasst von Yuwen Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Postgraduate Training Base Alliance of Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou, 325000, Zhejiang, Chi…. Hauptthemen laut MEDLINE: Cladribine, Adverse Drug Reaction Reporting Systems, Product Surveillance, Postmarketing, Immunosuppressive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Introduction
Cladribine has been widely recognized as a therapeutic option for relapsing–remitting multiple sclerosis (MS), but there is still a dearth of real-world data regarding its safety profile.
Aim
This study aimed to assess adverse events (AEs) linked to cladribine in MS patients, utilizing data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Method
AE reports identifying cladribine as the primary suspect drug were extracted from the U.S. FAERS, covering the period from the first quarter of 2019 to the third quarter of 2024. Four disproportionality methods—reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and empirical Bayes geometric mean—were employed to evaluate the association between cladribine and AEs. Furthermore, the Weibull distribution model was applied to analyze time-to-onset patterns, and subgroup analyses were conducted based on sex and age.
Results
After screening 4,833 cladribine-related reports, 113 preferred terms (PTs) were identified as positive across all four disproportionality methods. Known AEs such as pneumonia (n = 190, ROR 2.85), lymphopenia (n = 111, ROR 4.19), and drug-induced liver injury (n = 22, ROR 5.94). Unexpected events, including rheumatoid arthritis (ROR 5.64), hypothyroidism (ROR 5.04), eye hemorrhage (ROR 6.88), uveitis (ROR 4.86), retinal detachmen (ROR 4.37), brain edema (ROR 6.12), acute myocardial infarction (ROR 3.70), and completed suicide (ROR 7.46), were also reported. Stratified analysis revealed that females were at a higher risk of nausea, alopecia, and migraine, while males were more susceptible to gait disturbance and sepsis. Older adults (≥ 65 years) faced increased risks of leukopenia and urinary tract infections (UTIs). The median onset of AEs was 152 days, with the highest proportion (28.18%) reported in the first month. Weibull analysis indicated an early peak (shape parameter 0.72).
Conclusion
This study not only corroborates previously established risks associated with cladribine but also uncovers new potential safety signals, highlighting the importance of vigilance for early acute toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Postgraduate Training Base Alliance of Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou, 325000, Zhejiang, China.
- Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou, 325000, Zhejiang, China. yying33171@163.com.
- Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou, 325000, Zhejiang, China. 13736744198@163.com.
Förderung
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Hu, Y., He, J., Tu, Z., Ye, H., Zhuang, C., Jin, Z., Hu, H., Zhao, Y., Zheng, Y., & Yao, Q. (2025). Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-025-02041-8
Vancouver
Hu Y, He J, Tu Z, Ye H, Zhuang C, Jin Z, et al. Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system. International Journal of Clinical Pharmacy. 2025. doi:10.1007/s11096-025-02041-8
BibTeX
@article{Hu2025,
author = {Hu, Yuwen and He, Jianghai and Tu, Zheng and Ye, Hongyu and Zhuang, Caixiang and Jin, Ziyang and Hu, Haoxiang and Zhao, Yunhan and Zheng, Yanyan and Yao, Qiong},
title = {Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system},
journal = {International Journal of Clinical Pharmacy},
year = {2025},
doi = {10.1007/s11096-025-02041-8}
}
EUVIMED